Literature DB >> 23032594

Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy.

Taralyn M McCarrel1, Tom Minas, Lisa A Fortier.   

Abstract

BACKGROUND: Numerous methods are available for platelet-rich plasma (PRP) generation, but evidence defining the optimum composition is lacking. We hypothesized that leukocyte-reduced PRP would result in lower inflammatory cytokine expression compared with concentrated-leukocyte PRP and that maintaining the platelet:white blood cell (WBC) ratio would compensate for the effect of increased WBC concentration.
METHODS: Blood and flexor digitorum superficialis tendons were collected from young adult horses. Three PRP groups were generated with the same platelet concentration but different WBC concentrations: intermediate-concentration standard PRP, leukocyte-reduced PRP, and concentrated-leukocyte PRP. An additional high-concentration PRP group was generated with the same WBC concentration as the concentrated-leukocyte PRP group and the same platelet:WBC ratio as the standard PRP group. The PRP groups were used as media for flexor digitorum superficialis tendon explants in culture for seventy-two hours with 10% plasma in Dulbecco modified Eagle medium (DMEM) serving as control. Tendon gene expression for collagen types I (COL1A1) and III (COL3A1), cartilage oligomeric matrix protein (COMP), matrix metalloproteinase (MMP-13), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) was performed.
RESULTS: The desired PRP groups were successfully generated. The expression of COMP, the COL1A1:COL3A1 ratio, and the expression of MMP-13 in flexor digitorum superficialis tendon explants was not different between PRP groups. The expression of COMP (p = 0.0027) and the COL1A1:COL3A1 ratio (p < 0.0001) were increased in the PRP groups as compared with the control group, and the expression of MMP-13 was decreased in the PRP groups as compared with the control group (p < 0.0001). The expression of IL-1β was lowest in leukocyte-reduced PRP and highest in concentrated-leukocyte PRP (p = 0.0001). The leukocyte-reduced PRP group and the control group had the lowest TNF-α expression, whereas the high-concentration PRP and concentrated-leukocyte PRP groups had the highest expression (p = 0.0224).
CONCLUSIONS: A high absolute WBC concentration in PRP contributes to the expression of inflammatory cytokines in flexor digitorum superficialis tendon explants, and maintenance of the platelet:WBC ratio is not able to counteract this effect. CLINICAL RELEVANCE: The optimum composition of PRP for the treatment of tendinopathy has not been directly investigated. Persistent inflammation results in inferior repair with scar tissue. The present study indicates that in an animal model, WBC in PRP contributes to inflammatory cytokine production. Therefore, leukocyte-reduced PRP may be the optimum preparation to stimulate superior healing without scar tissue formation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23032594     DOI: 10.2106/JBJS.L.00019

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  101 in total

1.  Single ultrasound-guided platelet-rich plasma injection for treatment of supraspinatus tendinopathy in dogs.

Authors:  Louisa K Ho; Wendy I Baltzer; Sarah Nemanic; Susanne M Stieger-Vanegas
Journal:  Can Vet J       Date:  2015-08       Impact factor: 1.008

Review 2.  Augmenting tendon and ligament repair with platelet-rich plasma (PRP).

Authors:  Ting Yuan; Chang-Qing Zhang; James H-C Wang
Journal:  Muscles Ligaments Tendons J       Date:  2013-08-11

3.  Reply to letter to the editor: Platelet-rich plasma injections for chronic plantar fasciitis.

Authors:  Nicolò Martinelli
Journal:  Int Orthop       Date:  2013-10-11       Impact factor: 3.075

4.  Updates in biological therapies for knee injuries: tendons.

Authors:  Marco Kawamura Demange; Adriano Marques de Almeida; Scott A Rodeo
Journal:  Curr Rev Musculoskelet Med       Date:  2014-09

Review 5.  Platelet-Rich Plasma Promotes Axon Regeneration, Wound Healing, and Pain Reduction: Fact or Fiction.

Authors:  Damien P Kuffler
Journal:  Mol Neurobiol       Date:  2015-06-06       Impact factor: 5.590

6.  Reflections about the optimisation of the treatment of tendinopathies with PRP.

Authors:  Jean-François Kaux; Marc Bouvard; Christelle Lecut; Cécile Oury; André Gothot; Mikel Sanchez; Jean-Michel Crielaard
Journal:  Muscles Ligaments Tendons J       Date:  2015-03-27

7.  Commercial Separation Systems Designed for Preparation of Platelet-Rich Plasma Yield Differences in Cellular Composition.

Authors:  Ryan M Degen; Johnathan A Bernard; Kristin S Oliver; Joshua S Dines
Journal:  HSS J       Date:  2016-08-19

Review 8.  Platelet-rich plasma in tendon-related disorders: results and indications.

Authors:  Giuseppe Filardo; Berardo Di Matteo; Elizaveta Kon; Giulia Merli; Maurilio Marcacci
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-09-24       Impact factor: 4.342

9.  Combined intra-tendinous injection of Platelet Rich Plasma and bevacizumab accelerates and improves healing compared to Platelet Rich Plasma in tendinosis: comprehensive assessment on a rat model.

Authors:  Benjamin Dallaudiere; Olivier Zurlinden; Anne Perozziello; Lydia Deschamps; Ahmed Larbi; Liliane Louedec; Lionel Pesquer; Yohan Benayoun; Alain Silvestre; Jean Michel Serfaty
Journal:  Muscles Ligaments Tendons J       Date:  2014-11-17

Review 10.  Clinical Update: Why PRP Should Be Your First Choice for Injection Therapy in Treating Osteoarthritis of the Knee.

Authors:  Corey S Cook; Patrick A Smith
Journal:  Curr Rev Musculoskelet Med       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.